Russell Shonagh, Lim Felicia, Peters Pamela N, Wardell Suzanne E, Whitaker Regina, Chang Ching-Yi, Previs Rebecca A, McDonnell Donald P
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
Cancers (Basel). 2022 Aug 30;14(17):4219. doi: 10.3390/cancers14174219.
Despite advances in surgery and targeted therapies, the prognosis for women with high-grade serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy has minimally impacted outcomes in patients with ovarian cancer. Progress in this regard has been hindered by the lack of relevant syngeneic ovarian cancer models to study tumor immunity and evaluate immunotherapies. To address this problem, we developed a luciferase labeled murine model of high-grade serous ovarian cancer, STOSE.M1 luc. We defined its growth characteristics, immune cell repertoire, and response to anti PD-L1 immunotherapy. As with human ovarian cancer, we demonstrated that this model is poorly sensitive to immune checkpoint modulators. By developing the STOSE.M1 luc model, it will be possible to probe the mechanisms underlying resistance to immunotherapies and evaluate new therapeutic approaches to treat ovarian cancer.
尽管手术和靶向治疗取得了进展，但高级别浆液性卵巢癌女性患者的预后仍然很差。此外，与其他癌症不同，免疫疗法对卵巢癌患者的治疗效果影响甚微。由于缺乏相关的同基因卵巢癌模型来研究肿瘤免疫和评估免疫疗法，这方面的进展受到了阻碍。为了解决这个问题，我们开发了一种荧光素酶标记的高级别浆液性卵巢癌小鼠模型，即STOSE.M1 luc。我们确定了它的生长特征、免疫细胞组成以及对抗PD-L1免疫疗法的反应。与人类卵巢癌一样，我们证明该模型对免疫检查点调节剂的敏感性较差。通过开发STOSE.M1 luc模型，将有可能探究免疫疗法耐药的潜在机制，并评估治疗卵巢癌的新治疗方法。
